Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="De Wit, Stephane*" or (type exact bookEditor and editor="De Wit, Stephane*")

Add to list
- Journal Article
- A1
- open access
Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir

Jozefien De Clercq (UGent) , Marie-Angélique De Scheerder (UGent) , Virginie Mortier (UGent) , Chris Verhofstede (UGent) , Stefaan J. Vandecasteele, Sabine D. Allard, Coca Necsoi, Stephane De Wit, Sarah Gerlo (UGent) and Linos Vandekerckhove (UGent)

(2024) FRONTIERS IN IMMUNOLOGY. 14.
Add to list
- Journal Article
- A1
- open access
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Franco Maggiolo, Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove (UGent) , Juan Berenguer, Michelle L. D'Antoni, Christiana Blair, Susan K. Chuck, et al.

(2023) HIV MEDICINE. 24(1). p.27-36
Add to list
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

Rakan Nasreddine, Eric Florence, Jean Cyr Yombi, Sophie Henrard, Gilles Darcis, Jens Van Praet (UGent) , Linos Vandekerckhove (UGent) , Sabine D. Allard, Rémy Demeester, Peter Messiaen, et al.

(2023) HIV MEDICINE. 24(8). p.914-924
Add to list
- Conference Paper
- C3
- open access
Linking inducible HIV-1 reservoir to rebound after treatment interruption

Laurens Lambrechts (UGent) , Ytse Noppe (UGent) , Marion Pardons (UGent) , Basiel Cole, Sofie Rutsaert (UGent) , Stéphane De Wit, Guido Vanham, Eric Florence and Linos Vandekerckhove (UGent)

(2023) IAS 2023 Abstract Book. p.77-78
Add to list
- Journal Article
- A1
- open access
Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years : week 48 results of a phase 3b, open-label trial

Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove (UGent) , Juan Berenguer, Michelle L. D’Antoni, Christiana Blair, Susan K. Chuck, et al.

(2021) INFECTIOUS DISEASES AND THERAPY. 10(2). p.775-788
Add to list
Clinical characteristics and outcomes of COVID‐19 in people living with HIV in Belgium : a multicenter, retrospective cohort

Rakan Nasreddine, Eric Florence, Michel Moutschen, Jean‐Cyr Yombi, Jean‐Christophe Goffard, Inge Derdelinckx, Patrick Lacor, Linos Vandekerckhove (UGent) , Peter Messiaen, Stefaan Vandecasteele, et al.

(2021) JOURNAL OF MEDICAL VIROLOGY. 93(5). p.2971-2978
Add to list
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

Laura Dickinson, Rohan Gurjar, Wolfgang Stöhr, Stefano Bonora, Andrew Owen, Antonio D’Avolio, Adam Cursley, Jean-Michel Molina, Gerd Fäetkenheuer, Linos Vandekerckhove (UGent) , et al.

(2020) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 75(3). p.628-639
Add to list
- Journal Article
- A1
- open access
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription

Pieter Pannus, Sofie Rutsaert (UGent) , Stéphane De Wit, Sabine D. Allard, Guido Vanham, Basiel Cole (UGent) , Coca Nescoi, Joeri Aerts, Ward De Spiegelaere (UGent) , Achilleas Tsoumanis, et al.

(2020) JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 23(2).
Add to list
- Conference Paper
- C3
Analytical treatment interruption (ATI) in patients with very small HIV reservoir

Pieter Pannus, Sofie Rutsaert (UGent) , Stéphane De Wit, Guido Vanham, Coca Necsoi, Joeri Aerts, Ward De Spiegelaere (UGent) , Achilleas Tsoumanis, Marie Couttenye, Natacha Herssens, et al.

(2019) Retroviruses and Opportunistic infections, 26th Conference abstracts.
Add to list
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A Post, Stéphane De Wit, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Romana Petrovic, et al.

(2019) ANTIVIRAL RESEARCH. 170.

Academic Bibliography

Longitudinal patterns of inflammatory mediators after acute HIV infection correlate to intact and total reservoir

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

Linking inducible HIV-1 reservoir to rebound after treatment interruption

Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years : week 48 results of a phase 3b, open-label trial

Clinical characteristics and outcomes of COVID‐19 in people living with HIV in Belgium : a multicenter, retrospective cohort

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription

Analytical treatment interruption (ATI) in patients with very small HIV reservoir

Contents

Support

Contact